NCT04276597 2023-03-10
PUTNET
Excel Diagnostics and Nuclear Oncology Center
Phase 2 Withdrawn
Clinical Trials
6 trialsNCT04915144 2023-02-21
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
British Columbia Cancer Agency
Phase 2 Withdrawn
NCT04713202 2023-02-10
NET-PACS
Big Ten Cancer Research Consortium
Phase 2 Withdrawn
NCT04831567 2022-05-19
MIBNET
AC Camargo Cancer Center
Phase 2 Withdrawn
NCT04672876 2021-12-17
Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors
University of Chicago
Phase 2 Withdrawn
NCT01048086 2016-06-21
90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)
University of Iowa
Phase 2 Withdrawn